UHS Misses Non-GAAP Estimates But Beats Revenue Guidance

Universal Health (UHS) reported fiscal 2025 Q4 earnings on Feb 25, 2026, with revenue rising 9.1% to $4.49 billion and net income climbing 32.9% to $447.84 million. While GAAP EPS of $7.14 exceeded prior-year results, non-GAAP EPS of $5.88 missed estimates by $0.03, and revenue fell short by $20 million. The company provided 2026 guidance above consensus, forecasting net revenue of $18.42–$18.79 billion and adjusted EPS of $22.64–$24.52.

Revenue

Universal Health’s total revenue surged 9.1% year-over-year to $4.49 billion in Q4 2025, driven by robust demand across its healthcare services.

Earnings/Net Income

The company’s earnings per share (EPS) jumped 39.5% to $7.14, while net income rose 32.9% to $447.84 million, reflecting sustained profitability for over two decades. The EPS growth underscores strong profitability, though the non-GAAP EPS missed estimates by $0.03.

Price Action

UHS shares declined 0.32% in the latest trading day and 1.94% for the week but gained 12.50% month-to-date.

Post-Earnings Price Action Review

The strategy of buying UHS shares after a revenue drop quarter-over-quarter and holding for 30 days delivered moderate returns, with a CAGR of 10.32%, trailing the benchmark by 9.01 percentage points. The strategy faced a maximum drawdown of 44.60% and a Sharpe ratio of 0.31, indicating a challenging risk-return profile. Effective risk management remains critical in such volatile scenarios.

CEO Commentary

The CEO emphasized operational resilience amid industry headwinds, attributing revenue and EPS growth to disciplined cost management and strategic market expansion. Leadership highlighted investments in digital health solutions and outpatient services as priorities for 2026, expressing cautious optimism about navigating regulatory shifts and reimbursement challenges.

Guidance

Universal Health projected 2026 net revenue between $18.42 billion and $18.79 billion, above the $18.25 billion consensus, and adjusted EPS of $22.64–$24.52, exceeding the $23.49 estimate. The company reiterated confidence in long-term growth despite near-term pressures from ACA-related patient volume declines.

Additional News

Analysts revised price targets following the earnings release, with Barclays cutting its objective to $262 from $263 while maintaining an “overweight” rating. Wells Fargo reaffirmed an “equal weight” rating with a reduced price target of $235, down from $259. Guggenheim upgraded its rating to “buy” and raised its price target to $274. Meanwhile, a federal judge temporarily halted expansion of the 340B drug rebate program, a potential tailwind for hospital operators like UHS.